METHIMAZOLE- methimazole tablet Bionpharma Inc.

Methimazole Tablets, USP Rx only


DESCRIPTION

Methimazole, USP (1-methylimidazole-2-thiol) is a white to pale buff crystalline powder that is freely soluble in water, in alcohol, and in chloroform, and slightly soluble in ether. It differs chemically from the drugs of the thiouracil series primarily because it has a 5-instead of a 6-membered ring.

Methimazole tablet, USP contains 5 mg or 10 mg (43.8 µmol or 87.6 µmol) methimazole, USP an orally administered antithyroid drug.

Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, povidone K-30, and talc.

The molecular weight is 114.2 g/mol, and the molecular formula is C $_4$ H $_6$ N $_2$ S. The structural formula is as follows:



CLINICAL PHARMACOLOGY

Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection.

Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.

INDICATIONS AND USAGE

Methimazole tablets are indicated:

- In patients with Graves' disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option.
- To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

CONTRAINDICATIONS

Methimazole tablets are contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

WARNINGS

First Trimester Use of Methimazole and Congenital Malformations

Methimazole crosses the placental membranes and can cause fetal harm, when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received methimazole tablets in the first trimester of pregnancy. If methimazole tablets are used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.

Because of the risk for congenital malformations associated with use of methimazole tablets in the first trimester of pregnancy, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism. If methimazole tablets are used, the lowest possible dose to control the maternal disease should be given.

Agranulocytosis

Agranulocytosis is potentially a life-threatening adverse reaction of methimazole therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis or aplastic anemia (pancytopenia), and the patient's bone marrow indices should be monitored.

Liver Toxicity

Although there have been reports of hepatotoxicity (including acute liver failure) associated with methimazole, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction (anorexia, pruritus, right upper quadrant pain, etc.) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST). Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.

Hypothyroidism

Methimazole can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy (see **PRECAUTIONS, Pregnancy**).

Vasculitis

Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy. These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary hemorrhage, CNS vasculitis, and neuropathy. Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis. In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. If vasculitis is suspected, discontinue therapy and initiate appropriate intervention.

PRECAUTIONS

General

Patients who receive methimazole should be under close surveillance and should be cautioned to report immediately any evidence of illness, particularly sore throat, skin eruptions, fever, headache, or general malaise. In such cases, white-blood-cell and differential counts should be obtained to determine whether agranulocytosis has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause agranulocytosis.

Information for Patients

Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyroid drug, they should contact their physician immediately about their therapy.

Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole tablets. Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis (see **WARNINGS** and **ADVERSE REACTIONS**).

Laboratory Tests

Because methimazole may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures. Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of methimazole tablets should be employed.

Drug Interactions

<u>Anticoagulants (oral)</u>: Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures.

<u> β -adrenergic blocking agents</u>: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid.

<u>Digitalis glycosides</u>: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.

<u>Theophylline</u>: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year study, rats were given methimazole at doses of 0.5 mg/kg/day, 3 mg/kg/day, and 18 mg/kg/day. These doses were 0.3 time, 2 times, and 12 times the 15 mg/day maximum human maintenance dose (when calculated on the basis of surface area). Thyroid hyperplasia, adenoma, and carcinoma developed in rats at the two higher doses. The clinical significance of these findings is unclear.

Pregnancy

See WARNINGS

If methimazole tablets are used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.

In pregnant women with untreated or inadequately treated Graves' disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism.

Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery.

Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy during organogenesis.

Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to methimazole for the second and third trimesters.

Nursing Mothers

Methimazole is present in breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants who are nursed by mothers receiving treatment with methimazole. Monitor thyroid function at frequent (weekly or biweekly) intervals.

Pediatric Use

Because of postmarketing reports of severe liver injury in pediatric patient treated with propylthiouracil, methimazole is the preferred choice when an antithyroid drug is

required for a pediatric patient (see **DOSAGE AND ADMINISTRATION**).

ADVERSE REACTIONS

Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely. There have been postmarketing case reports of acute pancreatitis.

There are reports of a vasculitis, often associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications (see **WARNINGS**).

Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.

To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-BION or 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Signs and Symptoms

Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression. No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or death.

Treatment

To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.

In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's medical status.

DOSAGE AND ADMINISTRATION

Methimazole tablets are administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals.

Adults- The initial daily dosage is 15 mg for mild hyperthyroidism, 30 mg to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into

3 doses at 8-hour intervals. The maintenance dosage is 5 mg to 15 mg daily.

Pediatric- Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.

HOW SUPPLIED

Methimazole tablets, USP 5 mg - white to off-white, round, flat-faced, beveled-edged, functional scored tablets, engraved with "M" and "1" on either side of the score and plain on the other side.

They are available in:

Bottles of 100 NDC 69452-328-20

Methimazole tablets, USP 10 mg - white to off-white, round, flat-faced, beveled-edged, functional scored tablets, engraved with "M" and "2" on either side of the score and plain on the other side.

They are available in:

Bottles of 100 NDC 69452-329-20

STORAGE

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Dispense in tight, light-resistant container. Keep tightly closed.

Distributed by: Bionpharma Inc. Princeton, NJ 08540

MADE IN INDIA

Revised: September 2023

FDA-03

948026811

PRINCIPAL DISPLAY PANEL - 5 mg

NDC 69452-328-20

Methimazole Tablets, USP 5 mg

Rx only

100 Tablets

BIONPHARMA



PRINCIPAL DISPLAY PANEL - 10 mg

NDC 69452-329-20

Methimazole Tablets, USP 10 mg

Rx only

100 Tablets

BIONPHARMA

NDC 69452- 329 -20	Each tablet contains: Methimazol USUAL DOSAGE: See package ins			101
Methimazole	WARNING: This drug may cause the reactions occur, discontinue the doof patient is essential.	toxic reactions. If such Irug. Constant supervision	2920	0 53292
Tablets, USP	KEEP THIS AND ALL DRUGS OUT Dispense in a tight, light-resistant		52 33	6945 0000 00000
10 mg	Store at 20°C to 25°C (68°F to 77 15°C to 30°C (59°F to 86°F) [See Temperature].	°F); excursions permitted to USP Controlled Room	69452 32920	
Rx only 100 Tablets BIONPHARMA	Distributed by: Bionpharma Inc.	1122 N INDIA Code: TN/Drugs/TN0	948006779	GTIN Lot: Lot: SN: (

METHIMAZOLE						
methimazole tablet						
Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	ltem Co	de (Source)	NDC:	69452-328	
Route of Administration	ORAL					
Active Ingredient/Active Moiety						
Ingre	dient Name		Basis of Stren	gth	Strength	
METHIMAZOLE (UNII: 554Z48XN5E) (METHIMAZOLE - UNII:554Z48XN5E)			METHIMAZ OLE		5 mg	

Ingredient Name						Strength	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)							•
MAG	GNESIUM STE	RATE (UNII: 70097N	16130)				
STA	ARCH, CORN (U	NII: 08232NY3SJ)					
TAL	.C (UNII: 7SEV7J	4R1U)					
PO\	VIDONE K30 (U	NII: U725QWY32X)					
Pro	oduct Char	acteristics					
Col		white (off-white)			Score	2	pieces
	ape	ROUND (flat-faced, l	aveled-edged)		Size		mm
Fla	-		Jeveleu-eugeu)		Imprint Code		:1
	ntains				imprint code	141	, 1
Pa	ckaging						
	ckaging Item Code	Packa	ge Description	Mar	keting Start Date		ting End ate
# 1 ^N	Item Code		ge Description	Mar 03/25/2	Date		ting End ate
# 1 ^N	Item Code	100 in 1 BOTTLE; T			Date		-
# 1 ^N 2	Item Code NDC:69452-328- 20	100 in 1 BOTTLE; T Product	ype 0: Not a Combination		Date		-
# 1 ^N 2	Item Code NDC:69452-328- 20	100 in 1 BOTTLE; T	ype 0: Not a Combination		Date	D	ate
# 1	Item Code NDC:69452-328- 20	100 in 1 BOTTLE; T Product	ype 0: Not a Combination	03/25/2	Date	Da	ate
# 1	Item Code	100 in 1 BOTTLE; T Product	Type 0: Not a Combination	03/25/2 M	Date 2024 arketing Start	Da	ate eting End
# 1 ^N 2	Item Code	100 in 1 BOTTLE; T Product Information Application	Type 0: Not a Combination	03/25/2 M	Date 2024 arketing Start Date	Da	ate eting End
# 1 ^N 2	Item Code	100 in 1 BOTTLE; T Product Information Application	Type 0: Not a Combination	03/25/2 M	Date 2024 arketing Start Date	Da	ate eting Enc
# 1 2 Ma	Item Code	100 in 1 BOTTLE; T Product Information Application ANDA218149	Type 0: Not a Combination	03/25/2 M	Date 2024 arketing Start Date	Da	ate eting Enc

Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:69452-329			
Route of Administration	ORAL					
Active Ingredient/Active						

Active Ingredient/Active Moiety						
Ingredient Name	Basis of Strength	Strength				
METHIMAZOLE (UNII: 554Z48XN5E) (METHIMAZOLE - UNII:554Z48XN5E)	METHIMAZ OLE	10 mg				
Inactive Ingredients						
Ingredient Name	St	rength				
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)						
MAGNESIUM STEARATE (UNII: 70097M6I30)						
STARCH, CORN (UNII: 08232NY3SJ)						

POVIDONE K30 (UNII: U725QWY32X)							
Product Char	acteristics						
Color	white (off-white) Score			2 pieces			
Shape	ROUND (flat-faced, beveled-edged) Size		Size	8mm			
Flavor	Impr		Imprint Code		M;2		
Contains							
Packaging							
Packaging # Item Code	Package Description	Ma	arketing Start Date	Marl	keting End Date		
# Item Code	Package Description 100 in 1 BOTTLE; Type 0: Not a Combination Product		-	Marl	-		
# Item Code 1 NDC:69452-329-	100 in 1 BOTTLE; Type 0: Not a Combination		Date	Marl	-		
# Item Code 1 NDC:69452-329-	100 in 1 BOTTLE; Type 0: Not a Combination		Date	Marl	-		
 # Item Code 1 NDC:69452-329-20 	100 in 1 BOTTLE; Type 0: Not a Combination		Date	Marl	-		
 # Item Code 1 NDC:69452-329-20 	100 in 1 BOTTLE; Type 0: Not a Combination Product	03/25	Date		-		

Labeler - Bionpharma Inc. (079637826)

Registrant - Bionpharma Inc. (079637826)

Establishment

Name	Address	ID/FEI	Business Operations
OrBion Pharmaceuticals Private Limited		854403569	manufacture(69452-328, 69452-329)

Revised: 3/2024

Bionpharma Inc.